Email : info@otcjournal.com
URL : http://www.otcjournal.com
To
OTC Journal Members:
 |
Calypte Biomed
(OTC BB: CALY): Major Breakthrough; Lands First Order From West Africa |
|
Today, just after the market closed,
Calypte
Biomed announced the receipt of its first order from a West African
nation. This is a major breakthrough for the company, and could lead to
substantially higher sales in the near future.
We brought Calypte to the
attention of our members in our May
31st Trading Alert. This is the only company with an
FDA Approved test kit for the HIV Virus which uses urine
as opposed to blood for detection.
When we issued our Trading Alert
we rated the stock a buy up to $.17 with a short term price target of $.20.
We were wrong. The stock traded to a high of $.43 on July 9th, yielding
a 207% move in just six weeks. The stock's rapid appreciation
was fueled by the outstanding reception the test kits received at the semi
annual International AIDS conference held this past June in Barcelona,
Spain.
Their test is considerably less expensive
than traditional blood tests as the cost and risk of sample collection
is much simpler. In addition, urine samples don't have the expensive transportation
and storage costs at the laboratory associated with blood.
The test has been adopted by many
major North American insurance companies, but as pointed out in our May
31st Trading Alert, the international market for this revolutionary
new product far exceeds the insignificant US market.
 |
African
Market Estimated To Be Twenty Times the Size of North American Market |
 |
Last year's estimate has the total
number of HIV cases at about 750,000 in North America. On
the Sub Saharan African Continent there may be as many as 14 million
people infected with the AIDS virus. The spread of AIDS in Africa
has become a raging epidemic, and world health organizations are gearing
up to fight back. One can easily assume in order to stop the spread of
AIDS, first you have to identify who's got it.
The timing of this news release if
prophetic for investors who either made money and took their profits the
first time around, or wish they would have acted when we brought this situation
to their attention.
A quick look at the chart reveals
the stock has completed a round trip, and nearly returned to the level
where we first brought it to your attention. Therefore, we believe the
entry level at today's close is low risk as compared to the $.40 plus price
the stock attained in July.
Today's announcement represents a
major breakthrough for the company as this could be the first of many orders
originating out of the raging African Epidemic. Investors have been patiently
waiting for this company to establish an International presence, at the
time may have finally arrived.
Look for the stock to begin the rebound
process tomorrow.
Here is the complete text of the
news release for your review:
Wednesday August 7, 4:02 pm Eastern
Time
Press Release
SOURCE: Calypte Biomedical Corporation
Calypte Receives Initial Order
for Urine HIV Tests From West Africa
ALAMEDA, Calif., Aug. 7 /PRNewswire-FirstCall/
-- Calypte Biomedical Corporation (OTC Bulletin Board: CALY - News), the
developer and marketer of the only two FDA-approved HIV-1 Antibody tests
that can be used on urine samples announced today that it has received
its first West African order.
The order calls for delivery of the
company's Urine HIV-1 Screening and Supplemental Tests for use in Burkina
Faso. Burkina Faso, located in West Africa has a population of approximately
12 million, and according to the 2002 UNAIDS/WHO update, an adult HIV rate
of 6.5%. The 380,000 adults living with HIV/AIDS in Burkina Faso are evenly
divided between men and women, and there are also 61,000 children living
with HIV/AIDS. In 2001, Burkina had 44,000 deaths attributable to AIDS,
and a total of 270,000 children who have been orphaned by AIDS.
"Our first order is significant because
it represents our entry into a region of the world where the threat of
HIV/AIDS is extremely high," said Tony Cataldo, Chairman of Calypte. "We
would expect that as word of favorable experience with Calypte's urine
HIV tests spreads, this initial order should drive future sales, not only
in Burkina, but elsewhere in the region."
"West Africa, as a whole, has been
hard hit by the HIV epidemic. We are working with a Burkinabe distributor,
and anticipate that over the course of the next year we will expand our
activities into other countries in the region, such as Benin, Togo, Ivory
Coast, Mali, and Niger. Our test has been successfully used in several
African countries already, and we have every reason to believe that Burkina
Faso will derive the same benefits from the urine HIV tests as others have,"
said Nancy Katz, President and CEO of Calypte. "Previously published reports
regarding the use of the urine HIV tests in African settings have demonstrated
both the accuracy of the tests, as well as a greater willingness of people
to be voluntarily tested for HIV exposure with urine than with blood."
Calypte Biomedical Corporation, headquartered
in Alameda, California, is a public healthcare company dedicated to the
development and commercialization of urine-based diagnostic products and
services for Human Immunodeficiency Virus Type 1 (HIV-1), sexually transmitted
diseases and other infectious diseases. Calypte's tests include the screening
EIA and supplemental Western Blot tests, the only two FDA-approved HIV-1
antibody tests that can be used on urine samples. The company believes
that accurate, non-invasive urine-based testing methods for HIV and other
infectious diseases may make important contributions to public health by
helping to foster an environment in which testing may be done safely, economically,
and painlessly. Calypte markets its products in countries worldwide through
international distributors and strategic partners. Current product labeling
including specific product performance claims can be found on our website
at www.calypte.com .
Statements in this press release
that are not historical facts are forward-looking statements, including
statements regarding future revenues and sales projections, plans for future
financing, the ability to meet operational milestones, marketing arrangements
and plans, and shipments to and regulatory approvals in international markets.
Such statements reflect management's current views, are based on certain
assumptions and involve risks and uncertainties. Actual results, events,
or performance may differ materially from the above forward-looking statements
due to a number of important factors, and will be dependent upon a variety
of factors, including, but not limited to, our ability to obtain additional
financing that will allow us to continue our current and future operations
and whether demand for our product and testing service in domestic and
international markets will continue to expand. The Company undertakes no
obligation to publicly update these forward-looking statements to reflect
events or circumstances that occur after the date hereof or to reflect
any change in the Company's expectations with regard to these forward-looking
statements or the occurrence of unanticipated events. Factors that may
impact the Company's success are more fully disclosed in the Company's
most recent public filings with the U.S. Securities and Exchange Commission
("SEC"), including its annual report on Form 10-K for the year ended December
31, 2000 and its subsequent filings with the SEC.
For further information, please contact
Richard Van Maanen, International Business Devel. of Calypte Biomedical
Corporation, +1-510-749-5153; or Investor Relations, Joe Bunning of Sitrick
And Company, +1-310-788-2850, for Calypte Biomedical Corporation.
SOURCE: Calypte Biomedical Corporation
|
Charts Provided Courtesy
Of TradePortal.com
The OTC Journal is
a proud partner of the SwingWire.com
Online Investment Community. A next generation Online Analyst Exchange
providing Members the ability to search, review, track and monitor some
of the Internet's best Online CAs (CyberAnalysts). Members
have the opportunity to potentially achieve higher
returns by viewing top performing portfolios
and receiving real-time alerts from favorite CAs.
SwingWire.com
also has a lucrative incentive model for experienced investors and traders
who consistently outperform the market. Share market ideas with other like-minded
investors, establish a proven track record, provide insightful commentary,
attract followers and ultimately become one of the Internet's highest paid
and most sought after CyberAnalysts!
Click
here to receive your FREE 30-Day Trial Membership with no further obligation.
Sign Up Today!
|
